Defunct Company
Total Trials
13
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,102
NCT02228733
Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 30, 2014
Completion: Jan 31, 2015
NCT02454361
Safety, Tolerability and Pharmacokinetics of KBP-7072
Start: May 31, 2015
Completion: Dec 31, 2015
NCT02653014
Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment
Start: Jul 29, 2015
Completion: Mar 28, 2017
NCT02654626
A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects
Start: Oct 31, 2015
NCT02837237
Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
Start: Jul 13, 2016
Completion: Jun 30, 2017
NCT03340753
Bioavailability of KBP-5074 Tablet vs Capsule Formulations
Start: Oct 26, 2017
Completion: Dec 19, 2017
NCT03574363
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
Phase: Phase 2
Start: Apr 25, 2018
Completion: Aug 5, 2020
NCT04532957
A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects
Start: Aug 11, 2020
Completion: Oct 15, 2020
NCT04534699
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
Start: Aug 27, 2020
Completion: Nov 19, 2020
NCT04606537
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
Start: Oct 24, 2020
Completion: Nov 30, 2020
NCT04634812
Mass Balance Study of KBP-5074 in Healthy Male Subjects
Start: Dec 3, 2020
Completion: Dec 23, 2020
NCT04968184
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
Phase: Phase 3
Start: Nov 5, 2021
Completion: Jul 10, 2024
NCT05507463
Study of KBP-7072 in Healthy Male and Female Subjects
Start: Aug 16, 2022
Completion: Jun 29, 2023